Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses

Joelle Makoukji, Fadi Saadeh, Karl Albert Mansour, Sally El-Sitt, Jamal Al Ali, Nihar Kinarivala, Paul C. Trippier, Rose Mary Boustany

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Neuronal Ceroid Lipofuscinoses (NCL) are fatal inherited neurodegenerative diseases with established neuronal cell death and increased ceramide levels in brain, hence, a need for disease-modifying drug candidates, with potential to enhance growth, reduce apoptosis and lower ceramide in neuronal precursor PC12 cells and human NCL cell lines using enhanced flupirtine aromatic carbamate derivatives in vitro. Methods: Aromatic carbamate derivatives were tested by establishing growth curves under pro-apoptotic conditions and activity evaluated by trypan blue and JC-1 staining, as well as a drop in pro-apoptotic ceramide in neuronal precursor PC12 cells following siRNA knockdown of the CLN3 gene, and CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Ceramide levels were determined in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts before and after treatment. Expression of BCL-2, ceramide synthesis enzymes (CERS2/CERS6/SMPD1/DEGS2) and Caspases 3/8/9 levels were compared in treated versus untreated CLN3-deficient PC12 cells by qRT-PCR. Results: Retigabine, the benzyl-derivatized carbamate and an allyl carbamate derivative were neuroprotective in CLN3-defective PC12 cells and rescued CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts from diminished growth and accelerated apoptosis. All drugs decreased ceramide in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Increased BCL-2 and decreased ceramide synthesis enzyme expression were established in CLN3-derived PC12 cells treated with the benzyl and allyl carbamate derivatives. They down-regulated Caspase 3/Caspase 8 expression. Caspase 9 expression was reduced by the benzyl-derivatized carbamate. Interpretation: These findings establish that compounds analogous to flupirtine demonstrate anti-apoptotic activity with potential for treatment of NCL disease and use of ceramide as a marker for these diseases.

Original languageEnglish (US)
Pages (from-to)1089-1103
Number of pages15
JournalAnnals of Clinical and Translational Neurology
Volume5
Issue number9
DOIs
StatePublished - Sep 2018

Fingerprint

flupirtine
Neuronal Ceroid-Lipofuscinoses
Ceramides
PC12 Cells
Carbamates
Caspase 8
Therapeutics
Caspase 3
Growth
Apoptosis
Gene Knockdown Techniques
Trypan Blue
Caspase 9
Enzymes
Neurodegenerative Diseases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Makoukji, J., Saadeh, F., Mansour, K. A., El-Sitt, S., Al Ali, J., Kinarivala, N., ... Boustany, R. M. (2018). Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. Annals of Clinical and Translational Neurology, 5(9), 1089-1103. https://doi.org/10.1002/acn3.625

Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. / Makoukji, Joelle; Saadeh, Fadi; Mansour, Karl Albert; El-Sitt, Sally; Al Ali, Jamal; Kinarivala, Nihar; Trippier, Paul C.; Boustany, Rose Mary.

In: Annals of Clinical and Translational Neurology, Vol. 5, No. 9, 09.2018, p. 1089-1103.

Research output: Contribution to journalArticle

Makoukji, J, Saadeh, F, Mansour, KA, El-Sitt, S, Al Ali, J, Kinarivala, N, Trippier, PC & Boustany, RM 2018, 'Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses', Annals of Clinical and Translational Neurology, vol. 5, no. 9, pp. 1089-1103. https://doi.org/10.1002/acn3.625
Makoukji, Joelle ; Saadeh, Fadi ; Mansour, Karl Albert ; El-Sitt, Sally ; Al Ali, Jamal ; Kinarivala, Nihar ; Trippier, Paul C. ; Boustany, Rose Mary. / Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. In: Annals of Clinical and Translational Neurology. 2018 ; Vol. 5, No. 9. pp. 1089-1103.
@article{d583af7d98ce434cb2e6eca2fc97cf93,
title = "Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses",
abstract = "Objective: Neuronal Ceroid Lipofuscinoses (NCL) are fatal inherited neurodegenerative diseases with established neuronal cell death and increased ceramide levels in brain, hence, a need for disease-modifying drug candidates, with potential to enhance growth, reduce apoptosis and lower ceramide in neuronal precursor PC12 cells and human NCL cell lines using enhanced flupirtine aromatic carbamate derivatives in vitro. Methods: Aromatic carbamate derivatives were tested by establishing growth curves under pro-apoptotic conditions and activity evaluated by trypan blue and JC-1 staining, as well as a drop in pro-apoptotic ceramide in neuronal precursor PC12 cells following siRNA knockdown of the CLN3 gene, and CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Ceramide levels were determined in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts before and after treatment. Expression of BCL-2, ceramide synthesis enzymes (CERS2/CERS6/SMPD1/DEGS2) and Caspases 3/8/9 levels were compared in treated versus untreated CLN3-deficient PC12 cells by qRT-PCR. Results: Retigabine, the benzyl-derivatized carbamate and an allyl carbamate derivative were neuroprotective in CLN3-defective PC12 cells and rescued CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts from diminished growth and accelerated apoptosis. All drugs decreased ceramide in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Increased BCL-2 and decreased ceramide synthesis enzyme expression were established in CLN3-derived PC12 cells treated with the benzyl and allyl carbamate derivatives. They down-regulated Caspase 3/Caspase 8 expression. Caspase 9 expression was reduced by the benzyl-derivatized carbamate. Interpretation: These findings establish that compounds analogous to flupirtine demonstrate anti-apoptotic activity with potential for treatment of NCL disease and use of ceramide as a marker for these diseases.",
author = "Joelle Makoukji and Fadi Saadeh and Mansour, {Karl Albert} and Sally El-Sitt and {Al Ali}, Jamal and Nihar Kinarivala and Trippier, {Paul C.} and Boustany, {Rose Mary}",
year = "2018",
month = "9",
doi = "10.1002/acn3.625",
language = "English (US)",
volume = "5",
pages = "1089--1103",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses

AU - Makoukji, Joelle

AU - Saadeh, Fadi

AU - Mansour, Karl Albert

AU - El-Sitt, Sally

AU - Al Ali, Jamal

AU - Kinarivala, Nihar

AU - Trippier, Paul C.

AU - Boustany, Rose Mary

PY - 2018/9

Y1 - 2018/9

N2 - Objective: Neuronal Ceroid Lipofuscinoses (NCL) are fatal inherited neurodegenerative diseases with established neuronal cell death and increased ceramide levels in brain, hence, a need for disease-modifying drug candidates, with potential to enhance growth, reduce apoptosis and lower ceramide in neuronal precursor PC12 cells and human NCL cell lines using enhanced flupirtine aromatic carbamate derivatives in vitro. Methods: Aromatic carbamate derivatives were tested by establishing growth curves under pro-apoptotic conditions and activity evaluated by trypan blue and JC-1 staining, as well as a drop in pro-apoptotic ceramide in neuronal precursor PC12 cells following siRNA knockdown of the CLN3 gene, and CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Ceramide levels were determined in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts before and after treatment. Expression of BCL-2, ceramide synthesis enzymes (CERS2/CERS6/SMPD1/DEGS2) and Caspases 3/8/9 levels were compared in treated versus untreated CLN3-deficient PC12 cells by qRT-PCR. Results: Retigabine, the benzyl-derivatized carbamate and an allyl carbamate derivative were neuroprotective in CLN3-defective PC12 cells and rescued CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts from diminished growth and accelerated apoptosis. All drugs decreased ceramide in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Increased BCL-2 and decreased ceramide synthesis enzyme expression were established in CLN3-derived PC12 cells treated with the benzyl and allyl carbamate derivatives. They down-regulated Caspase 3/Caspase 8 expression. Caspase 9 expression was reduced by the benzyl-derivatized carbamate. Interpretation: These findings establish that compounds analogous to flupirtine demonstrate anti-apoptotic activity with potential for treatment of NCL disease and use of ceramide as a marker for these diseases.

AB - Objective: Neuronal Ceroid Lipofuscinoses (NCL) are fatal inherited neurodegenerative diseases with established neuronal cell death and increased ceramide levels in brain, hence, a need for disease-modifying drug candidates, with potential to enhance growth, reduce apoptosis and lower ceramide in neuronal precursor PC12 cells and human NCL cell lines using enhanced flupirtine aromatic carbamate derivatives in vitro. Methods: Aromatic carbamate derivatives were tested by establishing growth curves under pro-apoptotic conditions and activity evaluated by trypan blue and JC-1 staining, as well as a drop in pro-apoptotic ceramide in neuronal precursor PC12 cells following siRNA knockdown of the CLN3 gene, and CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Ceramide levels were determined in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts before and after treatment. Expression of BCL-2, ceramide synthesis enzymes (CERS2/CERS6/SMPD1/DEGS2) and Caspases 3/8/9 levels were compared in treated versus untreated CLN3-deficient PC12 cells by qRT-PCR. Results: Retigabine, the benzyl-derivatized carbamate and an allyl carbamate derivative were neuroprotective in CLN3-defective PC12 cells and rescued CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts from diminished growth and accelerated apoptosis. All drugs decreased ceramide in CLN1-/CLN2-/CLN3-/CLN6-/CLN8 patient-derived lymphoblasts. Increased BCL-2 and decreased ceramide synthesis enzyme expression were established in CLN3-derived PC12 cells treated with the benzyl and allyl carbamate derivatives. They down-regulated Caspase 3/Caspase 8 expression. Caspase 9 expression was reduced by the benzyl-derivatized carbamate. Interpretation: These findings establish that compounds analogous to flupirtine demonstrate anti-apoptotic activity with potential for treatment of NCL disease and use of ceramide as a marker for these diseases.

UR - http://www.scopus.com/inward/record.url?scp=85052400331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052400331&partnerID=8YFLogxK

U2 - 10.1002/acn3.625

DO - 10.1002/acn3.625

M3 - Article

C2 - 30250865

AN - SCOPUS:85052400331

VL - 5

SP - 1089

EP - 1103

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 9

ER -